RE:RE:RE:RE:RE:earnings multipleYeah, so they will need to pay 11x. Where else will they get a drug company for that price? It's a value buy.
d_trump wrote: My point is that CXR is not trading at 3 or 4 times earnings. Closer to 8. A strategic buyer might pay 13-14 times but its doubtful that Private Equity would pay that much expecially since the balance sheet is already levered.